2023-09-22
HC Andersen – Update on re-evaluation of Sparkle headline data
Magnus Corfitzen gives an update on re-evaluation of Sparkle headline data
Presentations & Articles
2023-09-12
Erik Penser Bank – Health Care Day
Deputy CEO and CCO presents at Erik Penser Health Care day.
2023-08-31
HC Andersen – Life Science Seminar
Chief Executive Officer presents at HC Andersen - Li
2023-08-23
HC Andersen – Half Year Report 2023
Chief Executive Officer presents at HC Andersen - Half Year Report 2023
2023-06-16
Ascelia Pharma – Valencia ESGAR
Q&A with liver imaging experts. European Society of Gastrointestinal and Adbominal Radiology (ESGAR) Annual Meeting in Valencia Spain, June 13-16, 2023.
2023-05-31
ABGSC Life Science Summit
CEO Magnus Corfitzen presents at ABG Investor Day
2023-05-25
Erik Penser Bank – Company Day
Chief Executive Officer presents at Erik Pensers Company Day
2023-04-28
Redeye Orphan Drug Day
CEO Magnus Corfitzen presents at Redeye Orphan Drug Day
2023-03-30
HC Andersen – Orviglance commercial opportunity and progress towards launch
Deputy Chief Executive Officer & CCO presents at HC Andersen
2023-03-13
Ascelia Pharma – Investor Update 14/03/2023
...
2023-02-16
HC Andersen – Q4 2022 highlights and Q&A
Chief Executive Officer presents at HC Andersen - Q4 2022 highlights and Q&A
2022-09-13
ABGSC Investor Day
CEO Magnus Corfitzen presents at ABG Investor Day
2022-05-31
HC Andersen – Oncology Seminar
Chief Executive Officer presents at HC Andersen Oncology Seminar
2022-05-19
Erik Penser Bank – Company Day
Chief Executive Officer presents at Erik Pensers Company Day
2022-04-27
Redeye Orphan Drug Day
Chief Medical Officer, Carl Bjartmar presents at Redeye Orphan Drug Day
2022-04-08
Oncoral featured in the journal International Pharmaceutical Industry
In the April edition of the International Pharmaceutical Industry Journal, you can read about the science and our work to improve the outcomes for gastric cancer patients through our innovative daily oral chemotherapy drug candidate, Oncoral (page 30-33)
2022-03-29
New Market Research Shows Strong Support for Orviglance
New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The research confirms the clear unmet need for an effective alternative to unenhanced MRI and a safe alternative to gadolinium contrast agents.
2022-03-03
A New Approach to Imaging Focal Liver Lesions in Patients With Reduced Kidney Function
A New Approach to Imaging Focal Liver Lesions in Patients With Reduced Kidney Function